Gaithersburg, MD – According to filings with the U.S. Securities and Exchange Commission, Arcellx Inc. is raising $83,681,224.00 in a new round of investment. Sources indicate as part of senior management President and Chief Executive Officer, David Hilbert played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Arcellx Inc.

Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland.  The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care.  Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease.

To learn more about Arcellx Inc., visit http://www.encartatx.com/

Contact:
David Hilbert, President and Chief Executive Officer
240-723-6641
https://www.linkedin.com/in/david-hilbert-15bbb516/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved